

## Earnings Review: First Real Estate Investment Trust (“FIRT”)

### Recommendation

- Counterparty credit risk and accumulation of trade receivables at FIRT has become a credit concern over the past 12 months. We are maintaining FIRT’s issuer profile at Neutral (5) for now, in view of FIRT’s properties being critical to LK/Siloam’s day-to-day healthcare business. We think rental payments to FIRT will continue to be supported, albeit with collection delays.
- FIRTSP 5.68%-PERP has widen since February 2018, nonetheless, we still see better value in Golden Agri Resources Ltd’s senior bonds, the GGRSP 4.75%’21, given its more senior structure. We think a differential of only 18 bps is still insufficient compensation on the FIRTSP 5.68%-PERP. We see FIRTSP 5.68%-PERP’s fair value at 100 bps wider and are currently Underweight the perpetuials.
- We have both FIRTSP and GGRSP’s issuer profile at Neutral (5).

### Relative Value:

Bond	Maturity/Call date	Aggregate leverage	Ask Yield	Spread
FIRTSP 5.68%-PERP	08/07/2021	33.5%	5.26%	316
GGRSP 4.75% '21	25/01/2021	49.0%*	5.02%	298

Indicative prices as at 18 April 2018 Source: Bloomberg

Aggregate leverage based on latest available quarter; debt-to-adjusted tangible assets used for GGRSP. We define adjusted tangible assets as total assets less intangibles, bearer plants and long term investments

**Issuer Profile:**  
**Neutral (5)**

Ticker: **FIRTSP**

### Background

Listed on the Singapore Stock Exchange (“SGX”) with a market cap of SGD1.1bn as at 18 April 2018, FIRT is a REIT that invests primarily in real estate used for healthcare and healthcare-related industries. Investment properties totaled SGD1.3bn as at 31 March 2018 and in FY2017, 96% of gross revenue was attributable to properties in Indonesia. FIRT is ~28%-owned by its Sponsor, Lippo Karawaci (“LK”).

Ezien Hoo, CFA

+65 6722 2215

[EzienHoo@ocbc.com](mailto:EzienHoo@ocbc.com)

### Key Considerations

- Increase in operating income driven by acquisitions:** FIRT reported its first quarter results for the financial year 2018 (“1Q2018”). Reported gross revenue was up 5.8% y/y to SGD28.7mn. This was driven by the full quarter contributions from Siloam Hospitals Buton & Lippo Plaza Buton (“Buton”, acquired in October 2017) and Siloam Hospitals Yogyakarta (“Jogja”, acquired in December 2017). EBITDA (based on our calculation which does not include other income and other expense) was SGD25.5mn (up 5.7% y/y), while finance cost was 10.7% higher y/y at SGD4.8mn following higher debt to finance the acquisition of Buton, Jogja and the second progress payment for the development of the new Siloam Hospitals Surabaya. Interest coverage as measured by EBITDA/Interest was 5.4x (1Q2017: 5.6x). In 1Q2018, FIRT paid SGD1.7mn in cash to perpetual holders. Taking 50% of this payment as interest, we find Adjusted EBITDA/Interest at 4.5x.
- Reported aggregate leverage manageable:** As at 31 March 2018, aggregate leverage was still manageable at 34% versus 33% in end-2017. FIRT is a non-traditional REIT which owns properties crucial to Sponsor’s underlying business operations. In our view, asset valuations for non-traditional REITs tend to be less certain versus a traditional REIT where properties are leased to third parties. Compounding the uncertainty, buying and selling of standalone hospitals happen infrequently (the only significant asset disposal at FIRT in the past five years had been an asset swap with Sponsor). As a mitigating factor, FIRT’s bank lenders have extended secured debt amounting to SGD378.2mn to FIRT as at 31 March 2018 (secured debt-to-total asset at 26%). With the exception of six healthcare properties (collectively valued at ~SGD167mn), secured debt are secured against all other FIRT’s properties, indicating a level of comfort over the marketability and valuation of assets. FIRT has identified certain Sponsor properties as its potential acquisition pipeline, though as of report date, no new acquisitions have been announced.
- Rising counterparty credit risk:** Moody’s has placed the “B1” corporate family rating of LK on a review for downgrade. In FY2017, 82.4% of rental income at FIRT was attributable to LK while 12.9% is attributable to PT Metropolitan Propertindo Utama (“PT MPU”) and its subsidiary. Another 0.4% of FIRT’s rental income was attributable to subsidiaries of PT Siloam International Hospitals Tbk

(~51%-owned by LK). Majority of FIRT's Indonesian properties are Master Leased to LK though the properties are used by Siloam for its day-to-day healthcare operations. We note a marked increase in trade receivable at FIRT as at 31 March 2018 to SGD31.4mn (end-2017: SGD26.0mn). Since end-2016, day sales receivable at FIRT had more than doubled from 40 days to 97 days in the current quarter, indicating this could be a knock-on effect from the tight liquidity at LK and a credit negative impact in our view.

- **Short term debt due:** Short term debt at FIRT was SGD109.9mn as at 31 March 2018, vis-à-vis SGD17.0mn in cash balance. Short term debt due is mostly consist of SGD100mn in bonds due on 22 May 2018 and these would need to be refinanced. While we think FIRT would be able to refinance such bonds, we note that this may come at a higher cost of funding on the back of counterparty credit risk concerns. We estimate that in FY2017, effective cost of borrowings at FIRT was 4.0% while secured debt was 77% of total debt in end-2017. In January 2018, FIRT had managed to raise SGD400mn in syndicated secured financing facilities from a bank lender. In early March 2018, these had been drawn down to refinance existing bank loans.

<b>OCBC Global Treasury</b>	
<p><b>Treasury Advisory</b>  <b>Corporate FX &amp; Structured Products</b>            Tel: 6349-1888 / 1881  <b>Interest Rate Derivatives</b>            Tel: 6349-1899  <b>Investments &amp; Structured Products</b>            Tel: 6349-1886</p> <p><b>GT Institutional Sales</b>            Tel: 6349-1810</p>	<p><b>Credit Research</b>  <b>Andrew Wong</b>            +65 6530 4736  <a href="mailto:WongVKAM@ocbc.com">WongVKAM@ocbc.com</a></p> <p><b>Nick Wong Liang Mian, CFA</b>            +65 6530 7348  <a href="mailto:NickWong@ocbc.com">NickWong@ocbc.com</a></p> <p><b>Ezien Hoo, CFA</b>            +65 6722 2215  <a href="mailto:EzienHoo@ocbc.com">EzienHoo@ocbc.com</a></p> <p><b>Wong Hong Wei</b>            +65 6722 2533  <a href="mailto:wonghongwei@ocbc.com">wonghongwei@ocbc.com</a></p>

#### Explanation of Issuer Profile Rating / Issuer Profile Score

**Positive (“Pos”)** – The issuer’s credit profile is either strong on an absolute basis, or expected to improve to a strong position over the next six months.

**Neutral (“N”)** – The issuer’s credit profile is fair on an absolute basis, or expected to improve / deteriorate to a fair level over the next six months.

**Negative (“Neg”)** – The issuer’s credit profile is either weaker or highly geared on an absolute basis, or expected to deteriorate to a weak or highly geared position over the next six months.

To better differentiate relative credit quality of the issuers under our coverage, we have further sub-divided our Issuer Profile Ratings into a 7 point Issuer Profile Score scale.

IPR	Positive		Neutral			Negative	
IPS	1	2	3	4	5	6	7

Explanation of Bond Recommendation

**Overweight (“OW”)** – The performance of the issuer’s specific bond is expected to outperform the issuer’s other bonds, or the bonds of other issuers either operating in the same sector or in a different sector but with similar tenor over the next six months.

**Neutral (“N”)** – The performance of the issuer’s specific bond is expected to perform in line with the issuer’s other bonds, or the bonds of other issuers either operating in the same sector or in a different sector but with similar tenor over the next six months.

**Underweight (“UW”)** – The performance of the issuer’s specific bond is expected to underperform the issuer’s other bonds, or the bonds of other issuers either operating in the same sector or in a different sector but with similar tenor over the next six months.

Other

**Suspension** – We may suspend our issuer rating and bond level recommendation on specific issuers from time to time when OCBC is engaged in other business activities with the issuer. Examples of such activities include acting as a joint lead manager or book runner in a new issue or as an agent in a consent solicitation exercise. We will resume our coverage once these activities are completed.

**Withdrawal (“WD”)** – We may withdraw our issuer rating and bond level recommendation on specific issuers from time to time when corporate actions are announced but the outcome of these actions are highly uncertain. We will resume our coverage once there is sufficient clarity in our view on the impact of the proposed action.

**Analyst Declaration**

The analyst(s) who wrote this report and/or her or his respective connected persons did not hold securities in the above-mentioned issuer or company as at the time of the publication of this report.

**Disclaimer for research report**

This publication is solely for information purposes only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our prior written consent. This publication should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities/instruments mentioned herein. Any forecast on the economy, stock market, bond market and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the securities/instruments. Whilst the information contained herein has been compiled from sources believed to be reliable and we have taken all reasonable care to ensure that the information contained in this publication is not untrue or misleading at the time of publication, we cannot guarantee and we make no representation as to its accuracy or completeness, and you should not act on it without first independently verifying its contents. The securities/instruments mentioned in this publication may not be suitable for investment by all investors. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. This publication may cover a wide range of topics and is not intended to be a comprehensive study or to provide any recommendation or advice on personal investing or financial planning. Accordingly, they should not be relied on or treated as a substitute for specific advice concerning individual situations. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase the investment product. OCBC and/or its related and affiliated corporations may at any time make markets in the securities/instruments mentioned in this publication and together with their respective directors and officers, may have or take positions in the securities/instruments mentioned in this publication and may be engaged in purchasing or selling the same for themselves or their clients, and may also perform or seek to perform broking and other investment or securities-related services for the corporations whose securities are mentioned in this publication as well as other parties generally.

This report is intended for your sole use and information. By accepting this report, you agree that you shall not share, communicate, distribute, deliver a copy of or otherwise disclose in any way all or any part of this report or any information contained herein (such report, part thereof and information, "**Relevant Materials**") to any person or entity (including, without limitation, any overseas office, affiliate, parent entity, subsidiary entity or related entity) (any such person or entity, a "**Relevant Entity**") in breach of any law, rule, regulation, guidance or similar. In particular, you agree not to share, communicate, distribute, deliver or otherwise disclose any Relevant Materials to any Relevant Entity that is subject to the Markets in Financial Instruments Directive (2014/65/EU) ("**MiFID**") and the EU's Markets in Financial Instruments Regulation (600/2014) ("**MiFIR**") (together referred to as "**MiFID II**"), or any part thereof, as implemented in any jurisdiction. No member of the OCBC Group shall be liable or responsible for the compliance by you or any Relevant Entity with any law, rule, regulation, guidance or similar (including, without limitation, MiFID II, as implemented in any jurisdiction).

Co.Reg.no.:193200032W